Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
An update from Affimed ( (AFMD) ) is now available.
On May 13, 2025, Affimed N.V. filed for insolvency in Mannheim, Germany, leading to a Nasdaq delisting notice on May 14, 2025. The Nasdaq Listing Qualifications Department decided to suspend trading of Affimed’s shares on May 20, 2025, due to public interest concerns, residual equity interest issues, and compliance challenges, impacting the company’s market presence.
The most recent analyst rating on (AFMD) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Affimed stock, see the AFMD Stock Forecast page.
Spark’s Take on AFMD Stock
According to Spark, TipRanks’ AI Analyst, AFMD is a Neutral.
Affimed’s overall stock score reflects its financial struggles, with declining revenue and increasing losses being major concerns. The stock is technically weak, and the valuation is challenging due to negative earnings. Positive aspects from the earnings call, such as strategic progress in clinical trials and reduced losses, provide some optimism but are outweighed by financial and operational challenges.
To see Spark’s full report on AFMD stock, click here.
More about Affimed
Affimed N.V. is a clinical-stage immuno-oncology company based in Mannheim, Germany, focused on empowering the innate immune system to combat cancer. The company develops innate cell engagers (ICE®) through its proprietary ROCK® platform, targeting both hematologic and solid tumors, with several ICE® molecules in clinical development.
Average Trading Volume: 275,985
Technical Sentiment Signal: Sell
Current Market Cap: $10.55M
See more data about AFMD stock on TipRanks’ Stock Analysis page.